{"id":30335,"date":"2022-06-27T13:21:00","date_gmt":"2022-06-27T05:21:00","guid":{"rendered":"https:\/\/flcube.com\/?p=30335"},"modified":"2025-03-25T13:28:55","modified_gmt":"2025-03-25T05:28:55","slug":"westlake-therapeutics-secures-rmb-100-million-in-series-a-funding-for-red-cell-therapy-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=30335","title":{"rendered":"Westlake Therapeutics Secures RMB 100 Million in Series A+ Funding for Red Cell Therapy Pipeline"},"content":{"rendered":"\n

Hangzhou-based cell therapy firm Westlake Therapeutics, founded in 2019, has successfully raised over RMB 100 million (USD 14.95 million) in a Series A+ financing round. The funding was led by EFung Capital, with participation from Ao Peng Investment, Hangzhou Westlake Science Innovation Equity Investment, and Westlake Innovation (Hangzhou) Equity Investment. The proceeds will be utilized to accelerate the development of a red cell platform product pipeline, clinical verification, and IND filing for red cell products.<\/p>\n\n\n\n

Company Background and Technology<\/strong>
As China’s first red blood cell (RBC) therapy company, Westlake Therapeutics offers the innovative RBC drug technology platform REDx. This platform enables the engineering of RBCs to carry various drugs into patients’ bodies for the treatment of major illnesses. The technology is the first of its kind in China and the second globally, following Rubius Therapeutics in Cambridge, Massachusetts.<\/p>\n\n\n\n

Product Pipeline and Future Outlook<\/strong>
Westlake Therapeutics is actively developing multiple product pipelines targeting rare diseases, tumors, autoimmune diseases, metabolic diseases, and other conditions. The recent funding will support the expansion of these pipelines and advance the clinical development of their innovative red cell-based therapies.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Hangzhou-based cell therapy firm Westlake Therapeutics, founded in 2019, has successfully raised over RMB 100…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,20,3895],"class_list":["post-30335","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biotech","tag-finance","tag-westlake-therapeutics"],"yoast_head":"\nWestlake Therapeutics Secures RMB 100 Million in Series A+ Funding for Red Cell Therapy Pipeline - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hangzhou-based cell therapy firm Westlake Therapeutics, founded in 2019, has successfully raised over RMB 100 million (USD 14.95 million) in a Series A+ financing round. The funding was led by EFung Capital, with participation from Ao Peng Investment, Hangzhou Westlake Science Innovation Equity Investment, and Westlake Innovation (Hangzhou) Equity Investment. The proceeds will be utilized to accelerate the development of a red cell platform product pipeline, clinical verification, and IND filing for red cell products.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=30335\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Westlake Therapeutics Secures RMB 100 Million in Series A+ Funding for Red Cell Therapy Pipeline\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=30335\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-27T05:21:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-25T05:28:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30335#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30335\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Westlake Therapeutics Secures RMB 100 Million in Series A+ Funding for Red Cell Therapy Pipeline\",\"datePublished\":\"2022-06-27T05:21:00+00:00\",\"dateModified\":\"2025-03-25T05:28:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30335\"},\"wordCount\":199,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biotech\",\"Finance\",\"Westlake Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30335#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30335\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=30335\",\"name\":\"Westlake Therapeutics Secures RMB 100 Million in Series A+ Funding for Red Cell Therapy Pipeline - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-06-27T05:21:00+00:00\",\"dateModified\":\"2025-03-25T05:28:55+00:00\",\"description\":\"Hangzhou-based cell therapy firm Westlake Therapeutics, founded in 2019, has successfully raised over RMB 100 million (USD 14.95 million) in a Series A+ financing round. The funding was led by EFung Capital, with participation from Ao Peng Investment, Hangzhou Westlake Science Innovation Equity Investment, and Westlake Innovation (Hangzhou) Equity Investment. The proceeds will be utilized to accelerate the development of a red cell platform product pipeline, clinical verification, and IND filing for red cell products.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30335#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30335\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30335#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Westlake Therapeutics Secures RMB 100 Million in Series A+ Funding for Red Cell Therapy Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Westlake Therapeutics Secures RMB 100 Million in Series A+ Funding for Red Cell Therapy Pipeline - Insight, China's Pharmaceutical Industry","description":"Hangzhou-based cell therapy firm Westlake Therapeutics, founded in 2019, has successfully raised over RMB 100 million (USD 14.95 million) in a Series A+ financing round. The funding was led by EFung Capital, with participation from Ao Peng Investment, Hangzhou Westlake Science Innovation Equity Investment, and Westlake Innovation (Hangzhou) Equity Investment. The proceeds will be utilized to accelerate the development of a red cell platform product pipeline, clinical verification, and IND filing for red cell products.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=30335","og_locale":"en_US","og_type":"article","og_title":"Westlake Therapeutics Secures RMB 100 Million in Series A+ Funding for Red Cell Therapy Pipeline","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=30335","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-06-27T05:21:00+00:00","article_modified_time":"2025-03-25T05:28:55+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=30335#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=30335"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Westlake Therapeutics Secures RMB 100 Million in Series A+ Funding for Red Cell Therapy Pipeline","datePublished":"2022-06-27T05:21:00+00:00","dateModified":"2025-03-25T05:28:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=30335"},"wordCount":199,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biotech","Finance","Westlake Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=30335#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=30335","url":"https:\/\/flcube.com\/?p=30335","name":"Westlake Therapeutics Secures RMB 100 Million in Series A+ Funding for Red Cell Therapy Pipeline - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-06-27T05:21:00+00:00","dateModified":"2025-03-25T05:28:55+00:00","description":"Hangzhou-based cell therapy firm Westlake Therapeutics, founded in 2019, has successfully raised over RMB 100 million (USD 14.95 million) in a Series A+ financing round. The funding was led by EFung Capital, with participation from Ao Peng Investment, Hangzhou Westlake Science Innovation Equity Investment, and Westlake Innovation (Hangzhou) Equity Investment. The proceeds will be utilized to accelerate the development of a red cell platform product pipeline, clinical verification, and IND filing for red cell products.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=30335#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=30335"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=30335#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Westlake Therapeutics Secures RMB 100 Million in Series A+ Funding for Red Cell Therapy Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30335","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30335"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30335\/revisions"}],"predecessor-version":[{"id":30337,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30335\/revisions\/30337"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30335"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30335"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30335"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}